Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 outbreak has profoundly changed daily routines, and similarly caused the suspension of spasticity treatment plans. Besides, the delay in botulinum toxin (BoNT) injection, which is important in the management of focal spasticity, led to some problems in children. This consensus report includes BoNT injection recommendations in the management of spasticity during the COVID-19 pandemic in children with CP. In order to develop the consensus report, physical medicine and rehabilitation (PMR) specialists experienced in the field of pediatric rehabilitation and BoNT injections were invited by Pediatric Rehabilitation Association. Items were prepared an...
In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children ...
OBJECTIVE: To determine safety of intramuscular botulinum toxin A (BoNT-A) injections to reduce spas...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 out...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with cerebral pal...
Botulinum toxin is a natural purified protein and one of the strongest biological poisons - neurotox...
Botulinum toxin A (BTA) inhibits presynaptic release of acetylcholine at the neuromuscular junction ...
Cerebral Palsy (CP) is a clinical condition that describes impairments of motor and sensory systems ...
Botulinum toxin type A (BTX-A) is increasingly bring used for the treatment of childhood spasticity,...
Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of n...
Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with cerebral pal...
Aim To validate a detailed intramuscular needle placement protocol using passive muscle stretching a...
Botulinum toxin type A can be both safe and effective in relieving spasticity in pediatric patients ...
In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children ...
OBJECTIVE: To determine safety of intramuscular botulinum toxin A (BoNT-A) injections to reduce spas...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...
Spasticity is the most common motor disturbance in cerebral palsy (CP). Lockdown in the COVID-19 out...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions in the ma...
Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with cerebral pal...
Botulinum toxin is a natural purified protein and one of the strongest biological poisons - neurotox...
Botulinum toxin A (BTA) inhibits presynaptic release of acetylcholine at the neuromuscular junction ...
Cerebral Palsy (CP) is a clinical condition that describes impairments of motor and sensory systems ...
Botulinum toxin type A (BTX-A) is increasingly bring used for the treatment of childhood spasticity,...
Cerebral palsy has an incidence of about 1-2 per 1000 live births, and in spite of the progress of n...
Botulinum toxin A (BoNT-A) is considered a safe and effective therapy for children with cerebral pal...
Aim To validate a detailed intramuscular needle placement protocol using passive muscle stretching a...
Botulinum toxin type A can be both safe and effective in relieving spasticity in pediatric patients ...
In the last 2 decades, BTX-A is increasingly being used in the management of spasticity in children ...
OBJECTIVE: To determine safety of intramuscular botulinum toxin A (BoNT-A) injections to reduce spas...
WOS: 000187502500005PubMed ID: 14643391The current modalities in managing spastic children have some...